Reply: Intravenous tocilizumab in the treatment of resistant optic perineuritis: a case report

Affiliations

¹ Massachusetts Eye Research and Surgery Institution, Waltham, Mass; The Ocular Immunology and Uveitis Foundation, Waltham, Mass.
² Massachusetts Eye Research and Surgery Institution, Waltham, Mass; The Ocular Immunology and Uveitis Foundation, Waltham, Mass; Harvard Medical School, Boston, Mass. Electronic address: sfoster@mersi.com.

Case Reports

Arash Maleki et al. Can J Ophthalmol. 2022 Aug.

. 2022 Aug;57(4):284-286.

doi: 10.1016/j.jcjo.2022.02.013. Epub 2022 Mar 10.

¹ Massachusetts Eye Research and Surgery Institution, Waltham, Mass; The Ocular Immunology and Uveitis Foundation, Waltham, Mass.
² Massachusetts Eye Research and Surgery Institution, Waltham, Mass; The Ocular Immunology and Uveitis Foundation, Waltham, Mass; Harvard Medical School, Boston, Mass. Electronic address: sfoster@mersi.com.

No abstract available

Comment on

Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis.
Maleki A, Manhapra A, Asgari S, Chang PY, Foster CS, Anesi SD. Maleki A, et al. Ocul Immunol Inflamm. 2021 Jan 2;29(1):14-20. doi: 10.1080/09273948.2020.1817501. Epub 2020 Oct 6. Ocul Immunol Inflamm. 2021. PMID: 33021415 Review.
Re: Intravenous tocilizumab in the treatment of resistant optic perineuritis: a case report.
Micieli JA, Margolin E. Micieli JA, et al. Can J Ophthalmol. 2022 Aug;57(4):284. doi: 10.1016/j.jcjo.2021.11.008. Epub 2021 Dec 21. Can J Ophthalmol. 2022. PMID: 34951960 No abstract available.